Determining antibody levels in humans is crucial for monitoring immunity against Covid-19 and tackling the national crisis. Antibody levels report about a previous infection and help decide whether people can return to work or live with others without spreading the disease. To be effective for national screening, antibody testing should deliver accurate results to individuals ideally within minutes, and be portable as well as high-throughput. Existing techniques based on immunosorbent assays do not deliver these benefits due to the need for multiple liquid handling steps, signal amplification, insufficient accuracy, or read-out with bulky optical equipment. This project will deliver fast, portable, high-throughput and accurate antibody sensing by pioneering step-changing sensor nanopores from the lead PI at University College London Chemistry (UCLC), and by integrating them into memory-stick-sized on-the-market kits from industrial partner and biotech unicorn Oxford Nanopore Technologies (ONT). These MinION analysis kits have ushered in a revolution in portable DNA sequencing and are currently used for unravelling the Covid-19 sequence. The PI has a strong working relationship with the company and has licensed sequencing pore technology which has been one key component to make the MinION a success. In this project, the technology will be adapted with wider nanopores tailored for Covid- 19 antibodies. The new sensor pores can be plugged into the existing MinION kits without the need for redesigning the device, thereby ensuring production to scale. The devices will be clinically tested and benchmarked by Co-PI and intensive care and monitoring specialist Prof. Mervyn Singer at UCL Medicine (UCLM). All project partners have previously successfully worked together in joint grants, for publications, or via technology licensing contracts.